Evaluating whether Genelux Corporation (GNLX) represents a sound investment requires understanding the inherent binary risks associated with clinical-stage biotechnology stocks. While optimistic investors look forward to upcoming clinical trial catalysts and innovative oncolytic viral immunotherapy pipelines, conservative financial analysts emphasize that pre-profit biotech equities carry high volatility, regulatory uncertainty, and potential capital dilution risks.